Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Verorab®
Verorab · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sinovac rabies vaccine | EXPERIMENTAL | Participants will be randomly assigned to receive Sinovac rabies vaccine. |
| Sanofi Pasteur Verorab® | ACTIVE_COMPARATOR | Participants will be randomly assigned to receive the marketed rabies vaccine Verorab® |
| Name | Type | Description |
|---|---|---|
| Rabies Vaccine (Serum-free Vero Cell), Freeze-dried | BIOLOGICAL | Receiving three doses of rabies vaccine rabies vaccine manufactured by Sinovac using a three-dose PrEP schedule |
| Verorab® | BIOLOGICAL | Receiving three doses of marketed rabies vaccine manufactured by Sanofi using the three-dose PrEP schedule |
Inclusion Criteria: 1. Populations aged ≥1 years old; 2. Participants and/or participants' parents/legal guardians are able to understand and sign the informed consent form (ICF) voluntarily; 3. Participants are able to comply with the study procedures based on the investigator's assessment; 4. In ...
Verorab is a rabies vaccine used for pre-exposure prophylaxis against rabies. It is being investigated in clinical trials for the prevention of rabies in healthy individuals. The vaccine is currently in clinical development and is not yet approved for use.
Verorab is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company. The company's stock is traded under the ticker symbol SVA. Sinovac is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
Verorab is in Phase 3 clinical development. It is being studied in a Phase 3 trial for pre-exposure prophylaxis against rabies. The vaccine is investigational and has not yet received regulatory approval. Additional Phase 2 trials are also ongoing.
Verorab is being evaluated in two clinical trials. NCT07055295 is a Phase 3 study of immunogenicity and safety in a pre-exposure prophylaxis regimen with 390 participants. NCT07055880 is a Phase 2 dose-finding study with 120 participants. Both trials are not yet recruiting and are being conducted in Pakistan.
Yes, Verorab and Verorab® refer to the same rabies vaccine. The registered trademark symbol is used in the product name. The vaccine is being developed by Sinovac Biotech, Ltd and is currently in Phase 3 clinical trials for rabies prevention.